Genmab A/S Sponsored ADR (NASDAQ:GMAB) Stock Has Average Price Target of $53.50 According to Brokerages

Genmab A/S logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is bullish: Twelve firms give Genmab a consensus “Buy” rating (10 Buy, one Strong Buy, and one Hold), with an average 12-month price target of $53.50. Several analysts recently raised their targets, including Guggenheim to $80 and HC Wainwright to $70.
  • Genmab reported quarterly earnings of $0.56 per share, beating the $0.36 consensus estimate, while revenue of $1.19 billion came in slightly below analyst expectations of $1.20 billion.
  • Institutional investors reported increased holdings, and the stock opened at $51.35, within its 52-week range of $23.62 to $59.97.
  • Five stocks we like better than Genmab A/S.

Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) have been assigned a consensus recommendation of "Buy" from the twelve research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $53.50.

Several analysts have weighed in on GMAB shares. Weiss Ratings upgraded Genmab A/S from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Monday, November 9th. HC Wainwright raised their price target on shares of Genmab A/S from $50.00 to $70.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. Guggenheim boosted their price objective on shares of Genmab A/S from $58.00 to $80.00 and gave the company a "buy" rating in a research report on Friday, October 30th. JPMorgan Chase & Co. upgraded shares of Genmab A/S from a "neutral" rating to an "overweight" rating in a report on Monday, October 26th. Finally, Truist Financial reissued a "buy" rating and issued a $67.00 target price (up from $45.00) on shares of Genmab A/S in a research note on Thursday, October 29th.

View Our Latest Analysis on GMAB

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds and other institutional investors have recently made changes to their positions in GMAB. Renaissance Technologies LLC lifted its position in Genmab A/S by 26.4% during the 1st quarter. Renaissance Technologies LLC now owns 4,414,550 shares of the company's stock valued at $118,442,000 after acquiring an additional 921,700 shares during the period. First Trust Advisors LP increased its stake in shares of Genmab A/S by 17.0% during the third quarter. First Trust Advisors LP now owns 3,225,639 shares of the company's stock valued at $115,075,000 after purchasing an additional 469,117 shares in the last quarter. Marshall Wace LLP increased its stake in shares of Genmab A/S by 47.0% during the third quarter. Marshall Wace LLP now owns 1,219,998 shares of the company's stock valued at $43,517,000 after purchasing an additional 390,339 shares in the last quarter. Pictet Asset Management Holding SA increased its stake in shares of Genmab A/S by 8.0% during the third quarter. Pictet Asset Management Holding SA now owns 1,150,854 shares of the company's stock valued at $41,044,000 after purchasing an additional 84,927 shares in the last quarter. Finally, Great Point Partners LLC purchased a new position in shares of Genmab A/S during the third quarter valued at approximately $18,729,000. Institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Up 0.7%

Shares of GMAB opened at $51.35 on Friday. The firm has a market cap of $32.05 billion, a price-to-earnings ratio of 43.89, a PEG ratio of 2.05 and a beta of 0.73. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.43 and a current ratio of 2.45. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $59.97. The firm has a 50 day moving average price of $42.62 and a 200-day moving average price of $31.97.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.36 by $0.20. Genmab A/S had a net margin of 16.97% and a return on equity of 13.67%. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.20 billion. As a group, equities research analysts forecast that Genmab A/S will post 1.28 earnings per share for the current year.

Genmab A/S Company Profile

(Get Free Report)

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases. The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Featured Stories

Analyst Recommendations for Genmab A/S (NASDAQ:GMAB)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines